Amgen Names Dr. Willard Dere Vice President, Global Inflammation Clinical Development
FOR IMMEDIATE RELEASE
THOUSAND OAKS, Calif., July 8, 2003 -- Amgen (Nasdaq:AMGN) today announced the appointment of Dr. Willard Dere to the position of vice president and head of the Inflammation Therapeutic Area, one of the company's three core research and development programs. Dr. Dere will oversee global development efforts for all new inflammation product candidates and new indications for Amgen's currently marketed inflammation therapies, ENBRELÆÊ (etanercept) and KineretÆÊ (anakinra).
"Drawing upon his strong industry expertise, Dr. Dere will make a significant contribution in advancing our clinical development of anti-inflammatory drugs, helping ensure Amgen's pipeline translates into important therapies for patients," said Dr. Beth Seidenberg, Amgen's senior vice president of development. "His role is critical as Amgen continues to build on its world-class inflammation franchise."
Dr. Dere joins Amgen after nearly 14 years at Eli Lilly & Company, where most recently he served as vice president of endocrine, bone and general medicine research and development. Dr. Dere led teams that successfully registered new therapies for osteoporosis. In addition, since 1989 Dr. Dere has held an academic appointment at Indiana University School of Medicine, where he was clinical associate professor, and hospital appointments at Wishard Memorial Hospital and Richard Roudebush Veterans Administration Medical Center, where he taught physical diagnosis and was an attending physician on the internal medicine service.
A California native, Dr. Dere received his medical and undergraduate degrees from the University of California at Davis. He pursued clinical training at the University of Utah Affiliated Hospitals and the University of California at San Francisco Affiliated Hospitals. He was an assistant professor at the University of Utah School of Medicine and held hospital appointments at the University of Utah Health Sciences Center and Veterans Administration Medical Center in Salt Lake City.
Dr. Dere has received numerous teaching awards from internal medicine housestaff and medical students, and has served on committees of several professional organizations, including the Pharmaceutical Research and Manufacturers of America, the American Society of Bone and Mineral Research and the Group for Respect, Excellence and Ethics in Science.
Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.
For further information, please contact: